4RM Stock Chart & Stats
€5.31
--
Market closed
€5.31
--
Day’s Range― - ―
52-Week Range€3.65 - €5.31
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€833.51K
Enterprise Value€12.56M
Total Cash (Recent Filing)€441.00K
Total Debt (Recent Filing)€11.99M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding3,609,471
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-52.62
Revenue Forecast (FY)€8.83M
Bulls Say, Bears Say
Bulls Say
Proprietary Non‑invasive 3D Mapping PlatformThe VIVO system is a differentiated, non‑invasive 3D electrocardiographic mapping platform that addresses a clinical need in electrophysiology. Its unique technology creates a durable competitive moat versus purely invasive mapping tools and supports long‑term adoption by EP labs as clinical utility accrues.
Recurring, Usage‑based Revenue PotentialThe business model includes per‑procedure and service/software revenue streams, which can scale with installed base and procedure volumes. Over months this supports more predictable recurring cash flows and higher lifetime customer value as site adoption and utilization increase.
Strategic Investment With Monetization RightsThe Volato private placement and registration rights create optionality: a diversified asset holding plus an enforceable path to monetize the stake. This provides a non‑operating source of liquidity and strategic flexibility that can help fund operations or reduce immediate external financing needs.
Bears Say
Sustained Negative Operating Cash FlowLarge, persistent negative operating and free cash flow indicate the company relies on external financing to fund operations. Over several months this constrains investment in commercialization and R&D, increases dilution risk, and limits financial flexibility unless cash generation meaningfully improves.
Very Small Revenue Base Vs Extreme LossesRevenue remains tiny relative to fixed costs, so even high percentage growth starts from a low base. Extreme negative margins show the cost structure outpaces sales, implying a lengthy scaling period to reach break‑even and continued dependence on financing during that scale phase.
Deteriorating Balance Sheet And Negative ReturnsModerate leverage coupled with dramatically negative ROE indicates the balance sheet is under strain as losses accumulate. Rising debt relative to equity reduces resilience to shocks and may elevate refinancing or covenant risk over a multi‑month horizon unless profitability or cash flow reverses.
Catheter Precision News
4RM FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was €3.65 and its highest was €5.31 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is €833.51K.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 22 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 3,609,471 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in DE:4RM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.